STOCK TITAN

Rosalind funds cap Delcath Systems (DCTH) stake at 9.9% with blockers

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Delcath Systems, Inc. received an amended Schedule 13D/A from the Rosalind group detailing their equity stake and governance role. Rosalind Advisors, Inc. reports beneficial ownership of 6,719,993 shares of common stock equivalents, representing 9.9% of the class after applying ownership blockers. These securities are primarily preferred stock and warrants that cannot be converted or exercised if ownership would exceed 9.99% for preferred shares or 4.99% for warrants. The percentages are based on 35,313,718 common shares outstanding as of October 27, 2025. Rosalind Master Fund L.P. reports 2,871,335 shares (4.4%), and Rosalind Opportunities Fund I L.P. reports 3,530,215 shares (4.9%). Steven Salamon and Gil Aharon, Canadian citizens and portfolio managers at Rosalind Advisors, also report 9.9% beneficial ownership each and serve as independent directors of Delcath, with board terms scheduled to run through the 2024 and 2025 annual meetings, respectively.

Positive

  • None.

Negative

  • None.





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
As more fully described in Item 5, the shares of Preferred Stock and Warrants are subject to a 9.99% blocker, and the percentage set forth in row (13) gives effect to such blockers. The securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (8), (10) and (11).


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:02/10/2026
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:02/10/2026
Aharon Gil
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:02/10/2026
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:02/10/2026
Rosalind Opportunities Fund I L.P.
Signature:Steven Salamon
Name/Title:Director, Rosalind Opportunities Fund I GP. Inc. (as General Partners to Rosalind Opportunities Fund I)
Date:02/10/2026

FAQ

What ownership stake does the Rosalind group report in Delcath Systems (DCTH)?

The Rosalind group reports beneficial ownership capped at 9.9% of Delcath’s common stock. This 9.9% figure is calculated against 35,313,718 shares outstanding as of October 27, 2025 and reflects contractual ownership blockers limiting further conversion or exercise.

How many Delcath Systems shares does Rosalind Advisors, Inc. beneficially own?

Rosalind Advisors, Inc. reports beneficial ownership of 6,719,993 shares of Delcath common stock equivalents. This amount reflects shares issuable upon full conversion and exercise of preferred stock and warrants, subject to ownership blockers that prevent the advisor from exceeding 9.99% of outstanding common shares.

What are the ownership blockers affecting Rosalind’s Delcath preferred stock and warrants?

Rosalind’s Delcath preferred stock cannot be converted if it would push ownership above 9.99% of outstanding common shares. Its warrants cannot be exercised if they would raise ownership above 4.99%. These blockers cap actual exercisable and convertible positions below theoretical maximums.

What stakes do Rosalind Master Fund L.P. and Rosalind Opportunities Fund I L.P. hold in Delcath?

Rosalind Master Fund L.P. reports 2,871,335 shares, representing 4.4% of Delcath’s common stock. Rosalind Opportunities Fund I L.P. reports 3,530,215 shares, representing 4.9%. Both percentages are calculated using 35,313,718 outstanding shares as of October 27, 2025.

What roles do Steven Salamon and Gil Aharon have at Delcath Systems and Rosalind?

Steven Salamon is President and portfolio manager of Rosalind Advisors, Inc. and an independent Class III director of Delcath, with a term scheduled to expire at the 2024 annual meeting. Gil Aharon is Secretary, portfolio manager, and a Class I director with a term expiring at the 2025 meeting.

How is the 9.9% Delcath ownership percentage for the Rosalind group calculated?

The 9.9% ownership percentage is based on 35,313,718 Delcath common shares outstanding as of October 27, 2025. It reflects the effect of contractual blockers that limit how much preferred stock can be converted and how many warrants can be exercised at any time.
Delcath Sys

NASDAQ:DCTH

DCTH Rankings

DCTH Latest News

DCTH Latest SEC Filings

DCTH Stock Data

345.26M
33.73M
2.72%
52.78%
8.7%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
QUEENSBURY